Ionpath
The business, the turning points, and the decisions behind them.
Some sections are still being researched1 / 4
Sections to complete：05
01 / WHAT IT BUILT
What the company did
Ionpath was a Menlo Park, California-based pioneer in high-definition spatial proteomics, co-founded by CEO Harris Fienberg and Stanford pathologist Mike Angelo. Its proprietary MIBIscope platform used multiplexed ion beam imaging (MIBI) to simultaneously image 40 or more individual proteins on a single slide with true subcellular resolution, serving immuno-oncology and translational research. The company closed an $18 million Series B round in September 2020 led by Samsara BioCapital with Bruker participating, and received a strategic investment from Thermo Fisher Scientific in 2022. In May 2023 it shifted to a services business, suspending standalone sales of MIBI instruments.
02 / Ionpath FAILURE REASONS
Failure factors
company ceased operations that Friday; he attributes root cause to 'time and money' (capital/runway). Oregon Physics later states it acquired MIBIscope IP/digital assets from previous manufacturer Ionpath in 2025, corroborating Ionpath exit as manufacturer.
'time and money are at the root' of cessation of operations.
03 / EVENT HISTORY
Events in the structured record
- Asset restructuring
The company entered an asset restructuring process.
- Asset restructuring
The company entered an asset restructuring process.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.